Cancer immunotherapies are designed to work in conjunction with a patient's immune system to increase native anti-tumor responses. In this field of study, conventional xenograft models lack relevance due to the animals’ immunocompromised status. A syngeneic mouse model, however, provides an effective approach for studying how cancer therapies perform in the presence of a functional immune system.
Charles River offers a broad range of syngeneic tumor models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1 and anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.
Now available! Use whole exome sequencing (WES) data to enhance your model selection, giving you the ability to choose based on mutation status as well as sensitivity to immune checkpoint inhibitors.
Request WES Information »